Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent

August 24, 2016

Type of Cancer

Myelodysplastic Syndrome

Site

Bethesda

Sponsor

Onconova Therapeutics, Inc.

Protocol Number

04-30

To Learn More Call

(201)-510-0950